Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2017 Jul 27;130(4):554-557.
doi: 10.1182/blood-2016-12-755496. Epub 2017 May 18.

DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study

Martin Bjerregård Pedersen  1 , Stephen Jacques Hamilton-Dutoit  2 , Knud Bendix  2 , Rhett P Ketterling  3 , Patrick P Bedroske  3 , Ivy M Luoma  3 , Christopher A Sattler  3 , Rebecca L Boddicker  3 , N Nora Bennani  4 , Peter Nørgaard  5 , Michael Boe Møller  6 , Torben Steiniche  2 , Francesco d'Amore  1 , Andrew L Feldman  3
Affiliations
Multicenter Study

DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study

Martin Bjerregård Pedersen et al. Blood. .
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Outcomes in patients with PTCL. (A) Five-year OS rates (Kaplan-Meier estimates) stratified by PTCL subtype and ALK status only (current WHO classification). (B) Five-year OS rates with ALK-negative ALCL stratified by genetic subtype. ALK-pos ALCL, anaplastic lymphoma kinase–positive anaplastic large cell lymphoma; ALK-neg DUSP22 ALCL, anaplastic lymphoma kinase–negative DUSP22-rearranged anaplastic large cell lymphoma; ALK-neg TP63 ALCL, anaplastic lymphoma kinase–negative TP63-rearranged anaplastic large cell lymphoma; −/−/− ALCL, triple-negative anaplastic large cell lymphoma (negative for ALK, DUSP22, and TP63).
See this image and copyright information in PMC

References

    1. Armitage JO. The aggressive peripheral T-cell lymphomas: 2015. Am J Hematol. 2015;90(7):665-673. - PubMed
    1. Vose J, Armitage J, Weisenburger D; International T-Cell Lymphoma Project. International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008;26(25):4124-4130. - PubMed
    1. Mak V, Hamm J, Chhanabhai M, et al. . Survival of patients with peripheral T-cell lymphoma after first relapse or progression: spectrum of disease and rare long-term survivors. J Clin Oncol. 2013;31(16):1970-1976. - PubMed
    1. Rowley JD. Chromosomal translocations: revisited yet again. Blood. 2008;112(6):2183-2189. - PubMed
    1. Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. . Evaluation of clinical trial eligibility and prognostic indices in a population-based cohort of systemic peripheral T-cell lymphomas from the Danish Lymphoma Registry. Hematol Oncol. 2015;33(4):120-128. - PubMed

Publication types

MeSH terms

Substances